Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Peter Clark, MA, MD, FRCP: A Payer Perspective

Deborah Collyar: What's In It for Patients?

Opportunities to Optimize Cancer Policies Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




May
19
Today In Oncology
Providing Culturally Sensitive Palliative Care to Children With Cancer
Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival
Definitive Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Cancer Comparison of Agents
FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive-Stage SCLC
Half-Matched Family Donors May Improve ASCT Outcomes in Hispanic Patients With ALL
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Designed by Harborside